From the BioCryst Pharmaceuticals, Inc. financial results for the first quarter ended 31 March 2022:

“We are now over a year into the ORLADEYO launch and are excited to see strong and continuing patient demand and steady expansion in our prescriber base among both new and existing prescribers. These trends continued in the first quarter of 2022,” says Jon Stonehouse, President and CEO of BioCryst. “We also have made substantial progress in our investigation with BCX9930. Based on our initial findings, we believe that both dose and dosing regimen could be contributing factors to the safety signal we have observed. By the end of the third quarter, we plan to discuss our proposed approach to resume the REDEEM trials, under a revised dosing protocol, with regulators.”

ORLADEYO has been launched in Denmark, France, Germany, Japan, Norway, Sweden, the United Arab Emirates, and the United Kingdom. The company expects launches in additional countries throughout the year.
(Source: BioCryst)